REFERENCES

  1. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004;62(8):1252–60.
  2. Brophy GM, Bell R, Claassen J, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care 2012;17(1):3–23.
  3. De Smedt T, Raedt R, Vonck K, Boon P. Levetiracetam: the profile of a novel anticonvulsant drug-part I: preclinical data. CNS Drug Rev. 2007 Spring;13(1):43-56. Doi: 10.1111/j.1527-3458.2007.00004.x.
  4. Nau KM, Divertie GD, Valentino AK, Freeman WD: Safety and efficacy of levetiracetam for critically ill patients with seizures. Neurocrit Care, 2009; 11(1): 34–37.
  5. Patsalos, P. (2000) ‘Pharmacokinetic profile of levetiracetam toward ideal characteristics.’, Pharmacology & Therapeutics, 85, pp.77-85.
  6. Patsalos PN, Berry DJ, Bourgeois BFD, Cloyd JC, Glauser TA, Johannessen SI, et al. Antiepileptic drugs - best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE commission on therapeutic strategies. Epilepsia 2008;49:1239–76. https://doi.org/ 10.1111/j.1528-1167.2008.01561.x
  7. Radtke, R.A. (2001), Pharmacokinetics of Levetiracetam. Epilepsia, 42: 24-27.https://doi.org/10.1111/j.1528-1167.2001.00005.
  8. Patsalos PN: Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet, 2004; 43(11): 707–24.
  9. Walker MC, Patsalos PN: Clinical pharmacokinetics of new antiepileptic drugs. Pharmacol Ther, 1995; 67(3): 351–84.
  10. DrugBank. Levetiracetam. Available at: https://go.drugbank.com/drugs/DB01202 (Accessed: 16 December 2021).
  11. EMC. Keppra 100 mg/ml concentrate for solution for infusion . Available at:https://www.medicines.org.uk/emc/product/2296/smpc#PHARMACOKINETIC_PROPS(Accessed: 8 December 2021).
  12. Strolin Benedetti M, Whomsley R, Nicolas J-M, Young C, Baltes E. Pharmacokinetics and metabolism of 14C-levetiracetam, a new antiepileptic agent, in healthy volunteers. Eur J Clin Pharmacol. 2003;59(8–9):621–30.
  13. Mora Rodríguez KA, Benbadis SR. Managing Antiepileptic Medication in Dialysis Patients. Curr Treat Options Neurol. 2018 Sep 27;20(11):45. doi: 10.1007/s11940-018-0530-5. PMID: 30259204.
  14. Tolwani A: Continuous renal-replacement therapy for acute kidney injury. New Engl J Med, 2012; 367(26): 2505–14.
  15. Case J, Khan S, Khalid R, Khan A. Epidemiology of acute kidney injury in the intensive care unit. Crit Care Res Pract. 2013;2013:479730. doi: 10.1155/2013/479730. Epub 2013 Mar 21. PMID: 23573420; PMCID: PMC3618922.
  16. Schetz M: Drug dosing in continuous renal replacement therapy: General rules. Curr Opin Crit Care, 2007; 13(6): 645–51.
  17. Ashley, C. and Dunleavy, A. The Renal Drug Database. Available at: https://renaldrugdatabase.com/ (Accessed: 13 April 2023).
  18. Shiue HJ, Taylor M, Sands KA. Comparison of Levetiracetam Dosing Regimens in End-Stage Renal Disease Patients Undergoing Intermittent Hemodialysis. Ann Pharmacother. 2017;51(10):862-865. doi:10.1177/1060028017713294, 10.1177/1060028017713294
  19. Wieruszewski PM, Kashani KB, Rabinstein AA, Frazee E. Levetiracetam Pharmacokinetics in a Critically Ill Anephric Patient on Intermittent Hemodialysis. Neurocrit Care. 2018;28(2):243-246. doi:10.1007/s12028-017-0441-4, 10.1007/s12028-017-0441-4.
  20. Smetana KS, Cook AM, Bastin ML, Oyler DR. Antiepileptic dosing for critically ill adult patients receiving renal replacement therapy. J Crit Care. 2016;36:116-124. doi:10.1016/j.jcrc.2016.06.023, 10.1016/j.jcrc.2016.06.023.
  21. Rodriguez, K. and Benbadis, S. (2018) ‘Managing Antiepileptic Medication in Dialysis Patients’, Current Treatment Options in Neurology, 20:45.
  22. Cuhls, M., Bosel, J. and Rosche, J. (2020) ‘Treatment with lacosamide or levetiracetam in patients with renal replacement therapy. What is really known?’, Journal of Epileptology , 28, pp.55-58.
  23. Araki, K. et al. (2020) ‘Pharmacological monitoring of antiepileptic drugs in epilepsy patients on haemodialysis.’, Epileptic Disorders , 22(1), pp. 90-102.
  24. Maia, J. et al. (2008) ‘Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate.’, International Journal of Clinical Pharmacology & Therapeutics , 46(3), pp.119-30.
  25. Nei, SD. et al. (2015) ‘Levetiracetam Pharmacokinetics in a Patient Receiving Continuous Venovenous Hemofiltration and Venoarterial Extracorporeal Membrane Oxygenation.’, Pharmacotherapy: The Journal of Human Pharmacology & Drug Therapy , 35(8), pp.127-30.
  26. Barker CI, Standing JF, Turner MA, et al. Antibiotic dosing in children in Europe: can we grade the evidence from pharmacokinetic/ pharmacodynamic studies - and when is enough data enough? Curr Opin Infect Dis. 2012 June;25(3):235–242.
  27. Gibney RT, Kimmel PL, Lazarus M. The Acute Dialysis Quality Initiative–part I: definitions and reporting of CRRT techniques. Adv Ren Replace Ther. 2002 Oct;9(4):252-4. doi: 10.1053/jarr.2002.35571. PMID: 12382226.
  28. Kellum JA, Mehta RL, Angus DC, Palevsky P, Ronco C, ADQI Workgroup. The first international consensus conference on continuous renal replacement therapy. Kidney Int 2002; 62: 1855–63.
  29. R Core Team (2022). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL: https://www.R-project.org/
  30. Wickham et al., (2019). Welcome to the tidyverse. Journal of Open Source Software, 4(43), 1686. DOI: https://doi.org/10.21105/joss.01686
  31. Rich B (2021). _linpk: Generate Concentration-Time Profiles from Linear PK Systems_. R package version 1.1.1. URL: https://CRAN.R-project.org/package=linpk
  32. Venables N. and Ripley B.D. (2002) Modern Applied Statistics with S. Fourth Edition. Springer, New York. ISBN 0-387-95457-0.
  33. le Noble JL, Foudraine NA, Kornips FH, van Dam DG, Neef C, Janssen PK. Extracorporeal Clearance of Levetiracetam During Continuous Venovenous Hemofiltration in a Critically Ill Patient and New Dosing Recommendation. J Clin Pharmacol. 2017 Apr;57(4):536-537. doi: 10.1002/jcph.844. Epub 2016 Nov 21. PMID: 27868207.
  34. New AM, Nei SD, Kashani KB, Rabinstein AA, Frazee EN. Levetiracetam Pharmacokinetics During Continuous Venovenous Hemofiltration and Acute Liver Dysfunction. Neurocrit Care. 2016 Aug;25(1):141-4. doi: 10.1007/s12028-016-0242-1. PMID: 26800696.
  35. Van Matre ET, Mueller SW, Fish DN, MacLaren R, Cava LF, Neumann RT, Kiser TH. Levetiracetam Pharmacokinetics in a Patient with Intracranial Hemorrhage Undergoing Continuous Veno-Venous Hemofiltration. Am J Case Rep. 2017 Apr 27;18:458-462. doi: 10.12659/ajcr.902709. PMID: 28446744; PMCID: PMC5414484.
  36. Louie JM, Raphael KL, Barker B. Levetiracetam Use With Continuous Renal Replacement Therapy. Ann Pharmacother. 2015 Sep;49(9):1079-80. doi: 10.1177/1060028015591845. Epub 2015 Jun 23. PMID: 26104053.
  37. Chappell K, Kimmons LA, Haller JT, Canada RB, He H, Hudson JQ. Levetiracetam pharmacokinetics in critically ill patients undergoing renal replacement therapy. J Crit Care. 2021 Feb;61:216-220. doi: 10.1016/j.jcrc.2020.10.032. Epub 2020 Nov 2. PMID: 33217623.
  38. Kalaria SN, Armahizer M, McCarthy P, Badjatia N, Gobburu JV, Gopalakrishnan M. A Practice-Based, Clinical Pharmacokinetic Study to Inform Levetiracetam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemofiltration (PADRE-01). Clin Transl Sci. 2020 Sep;13(5):950-959. doi: 10.1111/cts.12782. Epub 2020 Apr 3. PMID: 32223067; PMCID: PMC7485952.
  39. Kapur J, Elm J, Chamberlain JM, Barsan W, Cloyd J, Lowenstein D, Shinnar S, Conwit R, Meinzer C, Cock H, Fountain N, Connor JT, Silbergleit R; NETT and PECARN Investigators. Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus. N Engl J Med. 2019 Nov 28;381(22):2103-2113. doi: 10.1056/NEJMoa1905795.
  40. Haller JT, Bonnin S, Radosevich J. Rapid administration of undiluted intravenous levetiracetam. Epilepsia. 2021 Aug;62(8):1865-1870. doi: 10.1111/epi.16961. Epub 2021 Jun 24. PMID: 34164804.
  41. Wood KE, Palmer KL, Krasowski MD. Correlation of elevated lamotrigine and levetiracetam serum/plasma levels with toxicity: A long-term retrospective review at an academic medical center. Toxicol Rep. 2021 Aug 30;8:1592-1598. doi: 10.1016/j.toxrep.2021.08.005. PMID: 34522622; PMCID: PMC8424104.
  42. Silke Gastine, Asia N. Rashed, Yingfen Hsia, Charlotte Jackson, Charlotte I. S. Barker, Shrey Mathur, Stephen Tomlin, Irja Lutsar, Julia Bielicki, Joseph F. Standing & Mike Sharland (2019) GAPPS (Grading and Assessment of Pharmacokinetic-Pharmacodynamic Studies) a critical appraisal system for antimicrobial PKPD studies – development and application in pediatric antibiotic studies, Expert Review of Clinical Pharmacology, 12:12, 1091-1098, DOI: 10.1080/17512433.2019.1695600.
  43. Vaara S, Pettila V, Kaukonen KM. Quality of pharmacokinetic studies in critically ill patients receiving continuous renal replacement therapy. Acta Anaesthesiol Scand. 2012 Feb;56(2):147-57. doi: 10.1111/j.1399-6576.2011.02571.x. Epub 2011 Oct 19. PMID: 22092254.
  44. Kalaria, S.N., Armahizer, M., McCarthy, P. et al. Development and Use of an Ex-Vivo In-Vivo Correlation to Predict Antiepileptic Drug Clearance in Patients Undergoing Continuous Renal Replacement Therapy. Pharm Res 39, 827–836 (2022). https://doi.org/10.1007/s11095-022-03287-x.